Literature DB >> 407044

Alteration of plasma albumin in relation to decreased drug binding in uremia.

S W Boobis.   

Abstract

The binding of sulfadiazine in the plasma of normal and uremic subjects was measured by means of an ultrafiltration technique. Patients with uremia had reduced binding of sulfadiazine due to decreased albumin-binding capacity. No conclusive evidence was found to suggest that reduced drug binding in uremia is caused by competing metabolites. Studies of purified normal and uremic albumin revealed differences in amino acid composition and variations in the protein content of the two albumin bands found on isoelectric focusing. It is suggested that decreased drug binding in uremia may be at least partly due to altered albumin composition.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 407044     DOI: 10.1002/cpt1977222147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

3.  Pharmacokinetics of sufentanil in patients undergoing renal transplantation.

Authors:  P N Fyman; J R Reynolds; F Moser; M Avitable; P A Casthely; K Butt
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

4.  Haemodialysis does not affect the pharmacokinetics of nifedipine.

Authors:  H Martre; R Sari; A M Taburet; C Jacobs; E Singlas
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

5.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

6.  The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Authors:  Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

7.  Isolation and chemical characterization of 2-hydroxybenzoylglycine as a drug binding inhibitor in uremia.

Authors:  D M Lichtenwalner; B Suh; M R Lichtenwalner
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

8.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 9.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

10.  Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin.

Authors:  T J Dengler; G M Robertz-Vaupel; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.